Menu Search
Equities

Cidara Therapeutics Inc

CDTX:NAQ

Cidara Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)11.72
  • Today's Change0.10 / 0.86%
  • Shares traded27.97k
  • 1 Year change-44.19%
  • Beta1.0354
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Cidara Therapeutics Inc had relatively flat revenues (64.45m to 63.91m), though the company grew net income from a loss of 33.58m to a smaller loss of 22.93m. A reduction in the selling, general and administrative costs as a percentage of sales from 31.88% to 28.69% was a component in the net income growth despite flat revenues.
Gross margin91.14%
Net profit margin-367.91%
Operating margin-377.36%
Return on assets-96.27%
Return on equity-158.76%
Return on investment-136.45%
More ▼

Cash flow in USDView more

In 2023, Cidara Therapeutics Inc increased its cash reserves by 9.31%, or 3.05m. Cash Flow from Financing totalled 25.98m or 40.66% of revenues. In addition the company used 22.43m for operations while cash used for investing totalled 505.00k.
Cash flow per share-25.55
Price/Cash flow per share--
Book value per share28.66
Tangible book value per share28.66
More ▼

Balance sheet in USDView more

Cidara Therapeutics Inc uses little debt in its capital structure as supported by a debt to capital ratio of 0.53%.
Current ratio4.25
Quick ratio--
Total debt/total equity0.0053
Total debt/total capital0.0053
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.